Skip to content
About
Company Overview
Mission
Leadership
Science & Technology
Inflammation, Infection, & Tissue Injury
Zelpultide Alfa
Intellectual Property
Programs
Pipeline Overview
Bronchopulmonary dysplasia
Acute Respiratory Distress Syndrome (ARDS)
Pulmonary Fibrosis
Newsroom
Press Releases
In the Media
Resources
Clinical Trials Information
Publications & Presentations
Investor Resources
Careers
Contact Us
About
Company Overview
Mission
Leadership
Science & Technology
Inflammation, Infection, & Tissue Injury
Zelpultide Alfa
Intellectual Property
Programs
Pipeline Overview
Bronchopulmonary dysplasia
Acute Respiratory Distress Syndrome (ARDS)
Pulmonary Fibrosis
Newsroom
Press Releases
In the Media
Resources
Clinical Trials Information
Publications & Presentations
Investor Resources
Careers
Contact Us
In The Media
Daniele De Luca, MD, discusses zelpultide alfa in neonates at high risk of bronchopulmonary dysplasia development
November 21, 2025
©2026 Airway Therapeutics, Inc. All Rights Reserved.
Privacy Policy
|
Terms of Use
|
Accessibility Statement
|
Cookie Preferences
